Born in 2013, with offices in Barcelona, Spain, HiTT is an international market access consultancy with a payer perspective. Our main activities revolve around advising and working together with institutions, research centers and private companies in the healthcare sector, wishing to develop and implement innovative projects. HiTT’s team is dedicated to health and healthcare, we accumulate more than 30 years’ experience in implementing and producing solutions in both the field of research and healthcare.
Fostering innovation that contributes to the sustainability of the healthcare ecosystem.
Encourage public-private collaboration to improve health and deliver valuable healthcare.
Involvement, Commitment and Professionalism.
We focus our efforts and dedication to support companies, start-ups and institutions in the following areas of work
Expert consulting to support business strategic decission-making and investments in the healthcare sector.
MARKET ACCESS STRATEGIES
Trusted independent advisors with a payer’s perspective.
Striving to create innovative solutions for healthcare challenges.
NEWS & EVENTS
Add a subtitle in Customizer, "Latest news section"
The R&D response to the SARS-CoV-2 outbreak has been massive, promoted by unprecedented funding to support innovative solutions to fight the COVID-19 pandemic.
Clinical research is essential in contemporary medicine. It is a source of knowledge to improve healthcare, as it which is based on evidence. It helps to evaluate new drugs and , therapies. It is a a necessary step to test new assets but also to develop and gather advice from the best key opinion leaders.
Across all industries 9 out of 10 start-ups will fail. This staggering statistic doesn’t exactly inspire confidence. In healthcare the failure-rate may not be as detrimental but remains cause for concern. Which begs the question: why do so many start-ups fail?
HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license.
Oriol Sola Morales has collaborated in the creation of an article about reimbursement decisions on new oncology drugs. You can access to the entire article in this link.
Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures.
Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.
On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”